Ocular Therapeutix, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$52M
Cost of Revenue
$7M
R&D
$197M
D&A
$4M
Operating Income
$-270M
EBITDA
$-266M
Interest Expense
$12M
Tax Provision
$0
Net Income
$-266M
Operating Margin
-519.8%
Net Margin
-511.9%
Deferred Tax Assets
$3M
DTA Valuation Allowance
$292M
Tax Credit Carryforwards
$37M
NOL Carryforwards
$189M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
1.8%
Operating Lease Cost
$3M
Revenue YoY Variation
-18.5%
Income YoY Variation
-57.2%